Siren, L.L.C. Allovir, Inc. Transaction History
Siren, L.L.C.
- $2.26 Trillion
- Q4 2024
A detailed history of Siren, L.L.C. transactions in Allovir, Inc. stock. As of the latest transaction made, Siren, L.L.C. holds 6,597,167 shares of ALVR stock, worth $65.3 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
6,597,167
Previous 6,597,167
-0.0%
Holding current value
$65.3 Million
Previous $5.33 Billion
48.05%
% of portfolio
0.12%
Previous 0.27%
Shares
1 transactions
Others Institutions Holding ALVR
# of Institutions
52Shares Held
31.6MCall Options Held
14.9KPut Options Held
200-
Israel Englander Millennium Management LLC | New York, Ny3.03MShares$30 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.65MShares$26.2 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA1.91MShares$18.9 Million0.06% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ664KShares$6.58 Million0.0% of portfolio
-
Black Rock Inc. New York, NY634KShares$6.28 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $921M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...